Trial Profile
Effect of Macugen (Pegaptanib) on Surgical Outcomes and Growth Factors Including Vascular Endothelial Growth Factor (VEGF) Levels in Patients With Proliferative Diabetic Retinopathy (PDR) and Clinically Significant Diabetic Macular Edema (CSDME).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Pegaptanib (Primary)
- Indications Diabetic macular oedema; Diabetic retinopathy
- Focus Pharmacodynamics; Pharmacokinetics
- 03 Nov 2009 New trial record.